| Cardiovascular Exchange Summit 2011 |
| | Definitions |
|
| Global Burden of Obesity |
| | Trends in adult obesity from around the world |
|
| Type 2 Diabetes (T2DM) |
| | Obesity and Type 2 Diabetes |
|
| Diabetes and Weight Loss |
| | The Need to Feed |
|
| NICE clinical guideline 43 |
| | Treatment options |
|
| BARIATRIC SURGERY NICE GUIDELINES (CG43) |
| | Dieting vs. Bariatric Surgery |
|
| Procedures |
| | Types of Bariatric Surgery |
|
| Percent of excess weight lost post-surgery |
| | Health Benefits of Bariatric Surgery |
|
| Resolution of co-morbidities |
| | Risks of Bariatric Surgery |
|
| Nutritional Deficiencies |
| | Effect of operation on DM |
|
| T2DM & Bariatric Surgery |
| | Metabolic Surgery |
|
| Roux-en Y Gastric Bypass (RYGBP) ‘Gold standard’ |
|
|
| Gut hormones control body weight& blood sugar |
| | Ghrelin: a unique orexigenic hormone |
|
| Ghrelin stimulates hunger and food intake in normal-weight volunteers |
| | Obese subjects have reduced ghrelin levels |
|
| Peptide YY (PYY) |
| | Obese humans and mice have low circulating levels of PYY |
|
| Glucagon-like peptide 1 (GLP-1) |
| | Liraglutide |
|
| Liraglutide |
| | Increased food availability |
|
| PYY3-36 modulates homeostatic and reward regions |
| | Ghrelin modulates neuronal activity in homeostatic and reward regions |
|
| Role of ghrelin in obesity |
| | PYY and Dieting |
|
|
|
| | Ghrelin and Bariatric Surgery |
|
| Gastric bypass surgery reduces hunger and increases satiety |
| | Study Design |
|
| Anthropometric Data |
| | Appetite Ratings |
|
| Changes in PYY post-RYGB |
| | Changes in GLP-1 post-RYGB |
|
| Changes in acyl-ghrelin post-RYGB |
| | Are the changes in PYY3-36 and active GLP-1 due to weight loss? |
|
| Metabolic Surgery in T2DM with BMI ≤ 35 kg/m2 |
| | International Diabetes Federation |
|
| Take home messages |
| | How Does Obesity Surgery Cause Weight Loss and Cure Type 2 Diabetes? |
|
Deel deze pagina met collega's en vrienden: